Jian Sun

Antioxidative therapy has been considered an efficient strategy for the treatment of a series of excessive reactive oxygen species (ROS)-triggered diseases, including oxidative-stress-induced periodontal disease. However, current natural enzymes and nanozymes often show their high specificity toward given ROS and have insufficient antioxidative effects against multiple ROS generated in the diseases process. Meanwhile, multienzyme-based antioxidant defense systems are usually confined by the complicated synthesis as well as potential unwanted residue and toxicity. Various supports are highly needed to immobilize natural enzymes and antioxidants during the biorelated usages due to their low operational stability and difficulty of reuse. To overcome these limitations, we develop a high-performance platform by using biodegradable polydopamine nanoparticles (PDA NPs) as smart ROS scavengers in oxidative stress-induced periodontal disease. Although PDA-based materials are well-known to eliminate ROS both in vitro and in vivo, their antioxidative performance in periodontal disease and relative mechanisms have yet to be well-explored. In this study, PDA NPs can act as ROS scavengers in dental specialties with ideal outcomes. Spectroscopic and in vitro experiments provide strong evidence for the roles of PDA NPs in scavenging multiple ROS and suppressing ROS-induced inflammation reactions. In addition to the above investigations, the results from a murine periodontitis model clearly demonstrate the feasibility of PDA NPs as robust antioxidants with which to remove ROS and decrease periodontal inflammation without any side effects. Taken together, the results from our present study will provide valuable insight into the development of safe and efficient antioxidant defense platforms for further biomedical uses.

Various aspects of averaged modeling of hard-switching pulse-width modulated (PWM) converters operating in the discontinuous conduction mode (DCM) are studied. A more streamlined modeling procedure is proposed which serves as a general framework for comparing different models. A duty ratio constraint that defines the diode conduction interval is identified to be the key to accurate prediction of high-frequency behavior. A new duty-ratio constraint is proposed that leads to full-order averaged models of DCM converters. Numerical analyses and experimental measurements confirm that the new models correctly predict the small-signal responses up to one third of the switching frequency and are more accurate than all previous models. Moreover, new analytical results are included to show the origin of the high-frequency pole in DCM operation and to explain why the full-order model is capable of accurately predicting it. Averaged circuit counterparts of the new models are developed in the form of averaged switch models to facilitate circuit simulation.

Newly commercialized PEDOT:PSS products CLEVIOS PH1000 and FE-T, among the most conducting of polymers, show unexpectedly higher Seebeck coefficients than older CLEVIOS P products that were studied by other groups in the past, leading to promising thermoelectric (TE) power factors around 47 μW/m K(2) and 30 μW/m K(2) respectively. By incorporating both n and p type Bi(2)Te(3) ball milled powders into these PEDOT:PSS products, power factor enhancements for both p and n polymer composite materials are achieved. The contact resistance between Bi(2)Te(3) and PEDOT is identified as the limiting factor for further TE property improvement. These composites can be used for all-solution-processed TE devices on flexible substrates as a new fabrication option.

PURPOSE: To evaluate induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy versus up-front surgery and postoperative radiotherapy in patients with locally advanced resectable oral squamous cell carcinoma (OSCC). PATIENTS AND METHODS: A prospective open-label phase III trial was conducted. Eligibility criteria included untreated stage III or IVA locally advanced resectable OSCC. Patients received two cycles of TPF induction chemotherapy (docetaxel 75 mg/m(2) on day 1, cisplatin 75 mg/m(2) on day 1, and fluorouracil 750 mg/m(2) on days 1 to 5) followed by radical surgery and postoperative radiotherapy (54 to 66 Gy) versus up-front radical surgery and postoperative radiotherapy. The primary end point was overall survival (OS). Secondary end points included local control and safety. RESULTS: Of the 256 patients enrolled onto this trial, 222 completed the full treatment protocol. There were no unexpected toxicities, and induction chemotherapy did not increase perioperative morbidity. The clinical response rate to induction chemotherapy was 80.6%. After a median follow-up of 30 months, there was no significant difference in OS (hazard ratio [HR], 0.977; 95% CI, 0.634 to 1.507; P = .918) or disease-free survival (HR, 0.974; 95% CI, 0.654 to 1.45; P = .897) between patients treated with and without TPF induction. Patients in the induction chemotherapy arm with a clinical response or favorable pathologic response (≤ 10% viable tumor cells) had superior OS and locoregional and distant control. CONCLUSION: Our study failed to demonstrate that TPF induction chemotherapy improves survival compared with up-front surgery in patients with resectable stage III or IVA OSCC.

WS2 nanodots were prepared by liquid-phase exfoliation of bulk WS2 crystals in surfactant aqueous solution with the aid of ultrasonication. Their behaviors on catalyzing hydrogen evolution reaction (HER) were investigated after drop-casting them onto a glass carbon electrode. On the basis of the optical and electron characterizations, the nanodots were identified with a high concentration of octahedral phase of WS2 that showed better catalysis properties than the hexagonal WS2. From the polarization curve, the Tafel slope was estimated to be 51 mV per decade and the onset potential was 90 mV, indicating good catalytic performance of such nanodots. Our results suggest that surfactant-mediated exfoliation is an environmentally benign method to synthesize WS2 nanodots for improved catalyzing HER.